An Overview of the Factors Related to Leishmania Vaccine Development
Vaccines · 01.01.2026 · 14 (1) · 54
DOI: 10.3390/vaccines14010054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 01.01.2026. Verfasst von Luiz Felipe Domingues Passero und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente 11330-900, Brazil. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, LIM50-FMUSP, São Paulo State Research Foundation.
Abstract (Originalsprache)
Leishmaniasis is an infectious disease caused by several species of Leishmania parasites that preferentially infect macrophages as host cells. These intracellular parasites can evade the main microbicidal effector mechanisms of phagocytic cells and, in turn, are able to stimulate marked Th2 or regulatory T cell immune responses, which are not protective for the host. The presence of a non-protective immune response, together with the multiplication and spread of Leishmania parasites throughout the tissues, leads to the main clinical forms of leishmaniasis, such as cutaneous and visceral leishmaniasis. Although some clinical forms can be reproduced in experimental hosts such as mice and hamsters, these models do not fully mimic natural infection, which, in fact, impacts experimental vaccine development. For example, BALB/c mice are generally infected with around one million parasites, whereas humans are not infected with more than 1000 parasites, together with vector saliva. This excessive number of parasites in experimental models may affect the efficacy of vaccines in preclinical studies. Indeed, many experimental studies conducted over the past 20 years have shown only partial protection, regardless of the vaccine generation, host species employed, or the use of adjuvants. This review aims to summarize the main aspects associated with Leishmania vaccine development, including parasite diversity, host factors, immune responses, adjuvants, and antigens. Although many elegant studies have been conducted, it is possible that some essential step is still missing for the development of an effective vaccine for human use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente 11330-900, Brazil.
- Institute for Advanced Studies of Ocean (IEAMAR), São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178, São Vicente 11350-011, Brazil.
- Laboratory of Pathology of Infectious Diseases (LIM50), Department of Pathology, Medical School, São Paulo University, São Paulo 01246-903, Brazil.
ORCID-Profile: Luiz Felipe Domingues Passero, Italo Novais Cavallone, Gabriela Venicia Araújo Flores, Sarah Santos de Lima Melchert, Márcia Dalastra Laurenti
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- LIM50-FMUSP
- São Paulo State Research Foundation
- National Council for Scientific and Technological Development
Zitieren
APA
Passero, L. F. D., Cavallone, I. N., Araújo Flores, G. V., de Lima Melchert, S. S., & Laurenti, M. D. (2026). An Overview of the Factors Related to Leishmania Vaccine Development. Vaccines, 14(1), 54. https://doi.org/10.3390/vaccines14010054
Vancouver
Passero LFD, Cavallone IN, Araújo Flores GV, de Lima Melchert SS, Laurenti MD. An Overview of the Factors Related to Leishmania Vaccine Development. Vaccines. 2026;14(1):54. doi:10.3390/vaccines14010054
BibTeX
@article{Passero2026,
author = {Passero, Luiz Felipe Domingues and Cavallone, Italo Novais and Araújo Flores, Gabriela Venicia and de Lima Melchert, Sarah Santos and Laurenti, Márcia Dalastra},
title = {An Overview of the Factors Related to Leishmania Vaccine Development},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {1},
pages = {54},
doi = {10.3390/vaccines14010054}
}
EUVIMED